Hani Gabra

Q: What Schools Are Affiliated With Hani Gabra

Hani Gabra is affiliated with the following schools: Imperial College London, University of Oxford, University of Edinburgh, University of Glasgow

Hani Gabra's AcademicInfluence.com Rankings

Hani Gabra

Medical

#1939

World Rank

#2327

Historical Rank

Oncology

#152

World Rank

#158

Historical Rank

medical Degrees

Hani Gabra

Philosophy

#11142

World Rank

#15300

Historical Rank

Logic

#7993

World Rank

#9945

Historical Rank

philosophy Degrees

Download Badge

Medical
Philosophy

Why Is Hani Gabra Influential?

(Suggest an Edit or Addition)

According to Wikipedia, Hani Gabra PhD FRCPE FRCP is a British oncologist and Professor Emeritus in Medical Oncology at Imperial College London. Career Hani Gabra is a British academic medial oncologist and drug developer. He is Founder, board member and Chief Scientific Officer of Papyrus Therapeutics Inc., an emerging biotech company focussed on extra-cellular tumour suppressor therapies for cancer. He is also Professor Emeritus in Medical Oncology at Imperial College London and adjunct professor at the Centre for Cancer Biomarkers at the University of Bergen in Norway.

(See a Problem?)

Hani Gabra's Published Works

Number of citations in a given year to any of this author's works

Total number of citations to an author for the works they published in a given year. This highlights publication of the most important work(s) by the author

Published Works

Integrated Genomic Analyses of Ovarian Carcinoma (2011) (6411)
The Immune Landscape of Cancer (2018) (2766)
Oncogenic Signaling Pathways in The Cancer Genome Atlas (2018) (1646)
Comprehensive Characterization of Cancer Driver Genes and Mutations (2018) (1360)
Whole–genome characterization of chemoresistant ovarian cancer (2015) (1175)
Rethinking ovarian cancer: recommendations for improving outcomes (2011) (1148)
Rucaparib maintenance treatment for recurrent ovarian carcinoma after response to platinum therapy (ARIEL3): a randomised, double-blind, placebo-controlled, phase 3 trial (2017) (1039)
Rethinking ovarian cancer II: reducing mortality from high-grade serous ovarian cancer (2015) (778)
Adiposity and cancer at major anatomical sites: umbrella review of the literature (2017) (506)
Phase III randomized trial of docetaxel-carboplatin versus paclitaxel-carboplatin as first-line chemotherapy for ovarian carcinoma. (2004) (502)
Pathogenic Germline Variants in 10,389 Adult Cancers (2018) (501)
Comprehensive Analysis of Alternative Splicing Across Tumors from 8,705 Patients (2018) (471)
Copy-number signatures and mutational processes in ovarian carcinoma (2017) (258)
CpG island methylation of DNA damage response genes in advanced ovarian cancer. (2005) (248)
WWOX: A candidate tumor suppressor gene involved in multiple tumor types (2001) (243)
Risk factors for endometrial cancer: An umbrella review of the literature (2019) (227)
Randomized phase II placebo-controlled trial of maintenance therapy using the oral triple angiokinase inhibitor BIBF 1120 after chemotherapy for relapsed ovarian cancer. (2011) (204)
A prognostic model for ovarian cancer (2001) (195)
Expression of the serine protease matriptase and its inhibitor HAI-1 in epithelial ovarian cancer: correlation with clinical outcome and tumor clinicopathological parameters. (2002) (191)
Pan-Cancer Analysis of lncRNA Regulation Supports Their Targeting of Cancer Genes in Each Tumor Context (2018) (188)
c‐myc oncogene expression in colorectal cancer (1987) (187)
Antiestrogen Therapy Is Active in Selected Ovarian Cancer Cases: The Use of Letrozole in Estrogen Receptor–Positive Patients (2007) (185)
OPCML at 11q25 is epigenetically inactivated and has tumor-suppressor function in epithelial ovarian cancer (2003) (175)
HDAC4-regulated STAT1 activation mediates platinum resistance in ovarian cancer. (2011) (159)
CA125 response is associated with estrogen receptor expression in a phase II trial of letrozole in ovarian cancer: identification of an endocrine-sensitive subgroup. (2002) (156)
PPM1D Is a Potential Therapeutic Target in Ovarian Clear Cell Carcinomas (2009) (153)
Oxidative metabolism drives inflammation-induced platinum resistance in human ovarian cancer (2016) (128)
DNA-PK mediates AKT activation and apoptosis inhibition in clinically acquired platinum resistance. (2011) (128)
Genomic Analysis Reveals the Molecular Heterogeneity of Ovarian Clear Cell Carcinomas (2011) (123)
A 700-kb physical map of a region of 16q23.2 homozygously deleted in multiple cancers and spanning the common fragile site FRA16D. (2000) (113)
Definition and refinement of a region of loss of heterozygosity at 11q23.3-q24.3 in epithelial ovarian cancer associated with poor prognosis. (1996) (110)
LARP1 post-transcriptionally regulates mTOR and contributes to cancer progression (2014) (109)
Weekly dose-dense chemotherapy in first-line epithelial ovarian, fallopian tube, or primary peritoneal carcinoma treatment (ICON8): primary progression free survival analysis results from a GCIG phase 3 randomised controlled trial (2019) (109)
Carcinosarcoma of the ovary (2004) (108)
A mathematical-descriptor of tumor-mesoscopic-structure from computed-tomography images annotates prognostic- and molecular-phenotypes of epithelial ovarian cancer (2019) (107)
The RNA binding protein Larp1 regulates cell division, apoptosis and cell migration (2010) (105)
Ovarian Carcinomas: CCN Genes Are Aberrantly Expressed and CCN1 Promotes Proliferation of these Cells (2005) (96)
Obesity and gynaecological and obstetric conditions: umbrella review of the literature (2017) (96)
WWOX gene expression abolishes ovarian cancer tumorigenicity in vivo and decreases attachment to fibronectin via integrin alpha3. (2009) (95)
Continuous 5-fluorouracil in the treatment of breast cancer. (1994) (92)
A randomised, phase II trial of the DNA-hypomethylating agent 5-aza-2′-deoxycytidine (decitabine) in combination with carboplatin vs carboplatin alone in patients with recurrent, partially platinum-sensitive ovarian cancer (2014) (92)
The GAS6-AXL signaling network is a mesenchymal (Mes) molecular subtype–specific therapeutic target for ovarian cancer (2016) (91)
Chromatin H3K27me3/H3K4me3 histone marks define gene sets in high-grade serous ovarian cancer that distinguish malignant, tumour-sustaining and chemo-resistant ovarian tumour cells (2013) (76)
Biomarker Assessment of HR Deficiency, Tumor BRCA1/2 Mutations, and CCNE1 Copy Number in Ovarian Cancer: Associations with Clinical Outcome Following Platinum Monotherapy (2018) (72)
A study of symptoms described by ovarian cancer survivors. (2012) (71)
Endometrioid epithelial ovarian cancer (2008) (71)
Evaluation of an inflammation-based prognostic score in patients with advanced ovarian cancer. (2008) (71)
Extended weekly dose-dense paclitaxel/carboplatin is feasible and active in heavily pre-treated platinum-resistant recurrent ovarian cancer (2009) (68)
Platinum-Based Chemotherapy Induces Methylation Changes in Blood DNA Associated with Overall Survival in Patients with Ovarian Cancer (2016) (61)
Ovarian cancer: Ion channel and aquaporin expression as novel targets of clinical potential. (2013) (60)
BARX2 induces cadherin 6 expression and is a functional suppressor of ovarian cancer progression. (2001) (59)
p53 therapy in a patient with Li-Fraumeni syndrome (2007) (57)
A novel tumour marker related to the c-myc oncogene product. (1987) (57)
Chromosome 11 allele imbalance and clinicopathological correlates in ovarian tumours. (1995) (57)
A Randomized Phase II/III Study to Assess the Efficacy of Trametinib in Patients with Recurrent or Progressive Low-Grade Serous Ovarian or Peritoneal Cancer (2019) (57)
Wild-type and mutant p53 mediate cisplatin resistance through interaction and inhibition of active caspase-9 (2013) (55)
High frequency of chromosome 9 deletion in ovarian cancer: evidence for three tumour-suppressor loci. (1996) (54)
British Gynaecological Cancer Society (BGCS) epithelial ovarian/fallopian tube/primary peritoneal cancer guidelines: recommendations for practice. (2017) (54)
The IgLON Family in Epithelial Ovarian Cancer: Expression Profiles and Clinicopathologic Correlates (2005) (54)
Evolving concepts in the management of drug resistant ovarian cancer: dose dense chemotherapy and the reversal of clinical platinum resistance. (2013) (53)
Maximal-Effort Cytoreductive Surgery for Ovarian Cancer Patients with a High Tumor Burden: Variations in Practice and Impact on Outcome (2019) (50)
A phase Ib trial of docetaxel, carboplatin and erlotinib in ovarian, fallopian tube and primary peritoneal cancers (2008) (48)
WWOX mRNA expression profile in epithelial ovarian cancer supports the role of WWOX variant 1 as a tumour suppressor, although the role of variant 4 remains unclear. (2005) (48)
Rational treatment of chemotherapy-induced peripheral neuropathy with capsaicin 8% patch: from pain relief towards disease modification (2019) (47)
The OPCML tumor suppressor functions as a cell surface repressor-adaptor, negatively regulating receptor tyrosine kinases in epithelial ovarian cancer. (2012) (46)
Venous thromboembolism, interleukin-6 and survival outcomes in patients with advanced ovarian clear cell carcinoma. (2015) (46)
Risk of Ovarian Cancer Relapse Score (2014) (45)
A randomized phase II placebo-controlled trial using maintenance therapy to evaluate the vascular targeting agent BIBF 1120 following treatment of relapsed ovarian cancer (OC). (2009) (43)
A multicenter, randomized trial of flat dosing versus intrapatient dose escalation of single-agent carboplatin as first-line chemotherapy for advanced ovarian cancer: an SGCTG (SCOTROC 4) and ANZGOG study on behalf of GCIG. (2013) (42)
Expression of eEF1A2 is associated with clear cell histology in ovarian carcinomas: overexpression of the gene is not dependent on modifications at the EEF1A2 locus (2007) (42)
Inhibition of Carboplatin-Induced DNA Interstrand Cross-link Repair by Gemcitabine in Patients Receiving these Drugs for Platinum-Resistant Ovarian Cancer (2010) (41)
Functionality of the progesterone receptor in ovarian cancer and its regulation by estrogen. (1998) (39)
Endocrine therapy in epithelial ovarian cancer (2017) (39)
The role of interleukin-8 (IL-8) and IL-8 receptors in platinum response in high grade serous ovarian carcinoma (2015) (39)
TRAP1 downregulation in human ovarian cancer enhances invasion and epithelial–mesenchymal transition (2016) (38)
Identification of clinically relevant genes on chromosome 11 in a functional model of ovarian cancer tumor suppression. (2003) (38)
Value of Neoadjuvant Chemotherapy for Newly Diagnosed Advanced Ovarian Cancer: A European Perspective. (2017) (36)
Identification of proteomic and metabolic signatures associated with chemoresistance of human epithelial ovarian cancer. (2016) (33)
Identification of a region of frequent loss of heterozygosity at 11q24 in colorectal cancer. (1999) (32)
Phase IB Dose Escalation and Expansion Study of AKT Inhibitor Afuresertib with Carboplatin and Paclitaxel in Recurrent Platinum-resistant Ovarian Cancer (2018) (32)
Trametinib versus standard of care in patients with recurrent low-grade serous ovarian cancer (GOG 281/LOGS): an international, randomised, open-label, multicentre, phase 2/3 trial (2022) (32)
Correlation of pre-operative CT findings with surgical & histological tumor dissemination patterns at cytoreduction for primary advanced and relapsed epithelial ovarian cancer: A retrospective evaluation. (2016) (31)
The tumour suppressor OPCML promotes AXL inactivation by the phosphatase PTPRG in ovarian cancer (2018) (31)
Anti-tumour activity of a first-in-class agent NUC-1031 in patients with advanced cancer: results of a phase I study (2018) (30)
Safety, cost-effectiveness and feasibility of daycase paracentesis in the management of malignant ascites with a focus on ovarian cancer (2012) (30)
WWOX tumour suppressor gene polymorphisms and ovarian cancer pathology and prognosis. (2010) (30)
Maximal effort cytoreductive surgery for disseminated ovarian cancer in a UK setting: challenges and possibilities (2016) (29)
Exploring the clonal evolution of CD133/aldehyde-dehydrogenase-1 (ALDH1)-positive cancer stem-like cells from primary to recurrent high-grade serous ovarian cancer (HGSOC). A study of the Ovarian Cancer Therapy-Innovative Models Prolong Survival (OCTIPS) Consortium. (2017) (29)
Dose-Finding Quantitative 18F-FDG PET Imaging Study with the Oral Pan-AKT Inhibitor GSK2141795 in Patients with Gynecologic Malignancies (2015) (28)
Sexual activity and functioning in ovarian cancer survivors: an internet-based evaluation (2015) (28)
A Complex Network of Tumor Microenvironment in Human High-Grade Serous Ovarian Cancer (2017) (27)
Metabonomic analysis of ovarian tumour cyst fluid by proton nuclear magnetic resonance spectroscopy (2016) (27)
Weekly AUC2 carboplatin in acquired platinum-resistant ovarian cancer with or without oral phenoxodiol, a sensitizer of platinum cytotoxicity: the phase III OVATURE multicenter randomized study. (2014) (26)
Promising molecular targets in ovarian cancer (2009) (26)
Differential expression of IL-8 and IL-8 receptors in benign, borderline and malignant ovarian epithelial tumours. (2013) (26)
Oncologist-led BRCA ‘mainstreaming’ in the ovarian cancer clinic: A study of 255 patients and its impact on their management (2020) (26)
The Tumor-Suppressor Protein OPCML Potentiates Anti–EGFR- and Anti–HER2-Targeted Therapy in HER2-Positive Ovarian and Breast Cancer (2017) (25)
Weekly doxorubicin and continuous infusional 5-fluorouracil for advanced breast cancer. (1996) (24)
An unusual case of sex cord tumor with annular tubules with malignant transformation in a patient with Peutz-Jeghers syndrome. (2010) (23)
The molecular genetics of hereditary and sporadic ovarian cancer: implications for the future. (2014) (23)
Dynamics of the Intratumoral Immune Response during Progression of High-Grade Serous Ovarian Cancer1 (2018) (23)
Evaluation of 2-Deoxy-2-[18F]Fluoro-D-glucose- and 3′-Deoxy-3′-[18F]Fluorothymidine–Positron Emission Tomography as Biomarkers of Therapy Response in Platinum-Resistant Ovarian Cancer (2012) (23)
ZoptEC: Phase III randomized controlled study comparing zoptarelin with doxorubicin as second line therapy for locally advanced, recurrent, or metastatic endometrial cancer (NCT01767155). (2018) (22)
Diffusion-weighted MRI in Advanced Epithelial Ovarian Cancer: Apparent Diffusion Coefficient as a Response Marker. (2019) (21)
A putative biomarker signature for clinically effective AKT inhibition: correlation of in vitro, in vivo and clinical data identifies the importance of modulation of the mTORC1 pathway (2015) (21)
Homozygous deletions may be markers of nearby heterozygous mutations: The complex deletion at FRA16D in the HCT116 colon cancer cell line removes exons of WWOX (2008) (19)
The homeobox gene BARX2 can modulate cisplatin sensitivity in human epithelial ovarian cancer. (2002) (18)
Phase II study of DMXAA combined with carboplatin and paclitaxel in recurrent ovarian cancer. (2006) (18)
Phase Ib study of the mitochondrial inhibitor ME-344 plus topotecan in patients with previously treated, locally advanced or metastatic small cell lung, ovarian and cervical cancers (2017) (18)
Phase II study of letrozole in estrogen receptor (ER) positive relapsed epithelial ovarian cancer (EOC). (2006) (17)
AXL targeting restores PD-1 blockade sensitivity of STK11/LKB1 mutant NSCLC through expansion of TCF1+ CD8 T cells (2022) (17)
Methylation of MYLK3 gene promoter region: a biomarker to stratify surgical care in ovarian cancer in a multicentre study (2017) (16)
Corrigendum: Whole–genome characterization of chemoresistant ovarian cancer (2015) (16)
Loss of heterozygosity at 11q22 correlates with low progesterone receptor content in epithelial ovarian cancer. (1995) (16)
Identification and characterization of a homozygous deletion found in ovarian ascites by representational difference analysis. (1999) (16)
Integrative Analysis of Subcellular Quantitative Proteomics Studies Reveals Functional Cytoskeleton Membrane-Lipid Raft Interactions in Cancer. (2016) (16)
A study to evaluate the cause of bone demineralization in gynecological cancer survivors. (2013) (15)
WWOX sensitises ovarian cancer cells to paclitaxel via modulation of the ER stress response (2017) (15)
Frequency of mutations and polymorphisms in borderline ovarian tumors of known cancer genes (2013) (15)
Intra-uterine death resulting from placental metastases in adenocarcinoma of unknown primary. (2002) (15)
Molecular subtypes of serous borderline ovarian tumor show distinct expression patterns of benign tumor and malignant tumor-associated signatures (2014) (15)
A phase Ib trial of erlotinib (E) in combination with docetaxel (D) and carboplatin (C) in untreated ovarian, fallopian tube and primary peritoneal cancers. (2004) (15)
PISARRO: A EUTROC phase Ib study of APR-246 in combination with carboplatin (C) and pegylated liposomal doxorubicin (PLD) in platinum sensitive relapsed high grade serous ovarian cancer (HGSOC). (2016) (15)
Pharmacokinetic (PK)/pharmacodynamic (PD) analysis of escalating repeat doses of the AKT inhibitor GSK2141795 (GSK795) in patients (pts) with ovarian cancer. (2011) (14)
Plasma kisspeptin: a potential biomarker of tumor metastasis in patients with ovarian carcinoma. (2012) (14)
Anti-tumorigenic and Platinum-Sensitizing Effects of Apolipoprotein A1 and Apolipoprotein A1 Mimetic Peptides in Ovarian Cancer (2019) (14)
Malignant mixed mesodermal tumours: biology and clinical aspects. (2002) (14)
Introduction to managing patients with recurrent ovarian cancer (2014) (13)
A phosphoramidate ProTide (NUC-1031) and acquired and intrinsic resistance to gemcitabine. (2011) (13)
The RNA binding protein Larp 1 regulates cell division , apoptosis and cell migration (2010) (12)
Combined inhibition of the PI3K/mTOR/MEK pathway induces Bim/Mcl-1-regulated apoptosis in pancreatic cancer cells (2018) (12)
Future directions in the management of epithelial ovarian cancer. (2008) (11)
Intravenous Versus Oral Dexamethasone Premedication in Preventing Paclitaxel Infusion Hypersensitivity Reactions in Gynecological Malignancies (2013) (11)
Characterisation of tumour microvessel density during progression of high-grade serous ovarian cancer: clinico-pathological impact (an OCTIPS Consortium study). (2018) (11)
A feasibility study of sequential doublet chemotherapy comprising carboplatin-doxorubicin and carboplatin-paclitaxel for advanced endometrial adenocarcinoma and carcinosarcoma. (2009) (10)
Sustained platelet-sparing effect of weekly low dose paclitaxel allows effective, tolerable delivery of extended dose dense weekly carboplatin in platinum resistant/refractory epithelial ovarian cancer (2011) (10)
Endogenous aldehyde accumulation generates genotoxicity and exhaled biomarkers in esophageal adenocarcinoma (2021) (10)
Impact of lympho‐vascular space invasion on tumor characteristics and survival outcome of women with low‐grade serous ovarian carcinoma (2018) (10)
The Next Steps in Improving the Outcomes of Advanced Ovarian Cancer (2015) (9)
Cerebral sinus thrombosis and leptomeningeal carcinomatosis in a patient with ovarian cancer. (2012) (9)
Final results of ProGem1, the first in-human phase I/II study of NUC-1031 in patients with solid malignancies. (2015) (9)
5028 POSTER Update of phase II study of DMXAA (AS1404) combined with carboplatin and paclitaxel in recurrent ovarian cancer (2007) (9)
Safety and utility of image-guided research biopsies in relapsed high-grade serous ovarian carcinoma—experience of the BriTROC consortium (2017) (8)
Characterization of the urinary metabolic profile of cholangiocarcinoma in a United Kingdom population (2019) (8)
3 Afuresertib (GSK2110183), an oral AKT kinase inhibitor, in combination with carboplatin and paclitaxel in recurrent ovarian cancer (2014) (8)
[18F]Fluciclatide PET as a biomarker of response to combination therapy of pazopanib and paclitaxel in platinum-resistant/refractory ovarian cancer (2019) (8)
A protective role for common p21WAF1/Cip1 polymorphisms in human ovarian cancer. (1999) (8)
Inactivating mutations and X-ray crystal structure of the tumor suppressor OPCML reveal cancer-associated functions (2019) (8)
Back to the future: Targeting molecular changes for platinum resistance reversal. (2010) (7)
The association between obesity and weight loss after bariatric surgery on the vaginal microbiota (2020) (7)
Proteomic analysis of malignant and benign endometrium according to obesity and insulin-resistance status using Reverse Phase Protein Array. (2019) (7)
High-dose chemotherapy supported by peripheral blood progenitor cells in poor prognosis metastatic breast cancer--phase I/II study. Edinburgh Breast Group. (1996) (6)
[Effect of WWOX gene on the attachment and adhesion of ovarian cancer cells]. (2009) (6)
EUTROC PiSARRO: A phase Ib study combining APR-246 with standard chemotherapy in platinum sensitive relapsed high grade serous ovarian carcinoma (HGSOC). (2015) (6)
Dose density and altered scheduling of adjuvant chemotherapy in ovarian cancer: teaching old dogs new tricks? (2009) (6)
ProGem1: Phase I first-in-human study of the novel nucleotide NUC-1031 in adult patients with advanced solid tumors [Abstract] (2013) (6)
Randomized trial of intrapatient dose escalation of single agent carboplatin as first-line treatment for advanced ovarian cancer: An SGCTG study (SCOTROC 4). (2009) (6)
Targeting locoregional peritoneal dissemination in ovarian cancer (2009) (6)
First-line therapy for ovarian cancer with carboplatin followed by paclitaxel-gemcitabine (SCOTROC5): a feasibility study and comparative analysis of the SCOTROC series. (2010) (5)
OCTOPUS: A randomised, multi-centre phase II umbrella trial of weekly paclitaxel+/- novel agents in platinum-resistant ovarian cancer—Vistusertib (AZD2014). (2017) (5)
A first in human Phase I/II study of NUC-1031 in patients with advanced gynecological cancers. (2015) (5)
Clinical value of bioelectrical properties of cancerous tissue in advanced epithelial ovarian cancer patients (2018) (5)
Emerging roles for the GPI-anchored tumor suppressor OPCML in cancers (2020) (4)
Response to sunitinib (Sutent) in chemotherapy refractory clear cell ovarian cancer (2016) (4)
Epithelial Ovarian Cancer (2012) (4)
Surgery for Recurrent Uterine Cancer: Surgical Outcomes and Implications for Survival—A Case Series (2017) (4)
Response to neoadjuvant chemotherapy in ICON8: A GCIG phase III randomised trial evaluating weekly dose-dense chemotherapy integration in first-line epithelial ovarian/ fallopian tube/ primary peritoneal carcinoma (EOC) treatment. (2018) (3)
Continuous low-flow ascites drainage and sequential non-invasive tumor-cell sampling through the urinary bladder via the alfa-pump closed system in platinum-resistant ovarian cancer (PROC): First clinical experience in a cancer patient. (2013) (3)
CA125 response and disease stabilisation are associated with estrogen receptor expression in a phase II trial of letrozole in ovarian cancer (2001) (3)
362 A PhII study of bemcentinib, a first-in-class selective AXL kinase inhibitor, in combination with pembrolizumab in pts with previously-treated advanced NSCLC: Updated clinical & translational analysis (2020) (3)
Copy number signatures and mutational processes in ovarian carcinoma (2018) (3)
p 53 therapy in a patient with Li-Fraumeni syndrome (2007) (3)
Identification of functional modulators of platinum resistance using isogenically matched ovarian cancer cell line models. (2008) (3)
Phase I/II dose-escalation and expansion study of afuresertib + carboplatin and paclitaxel in recurrent ovarian cancer. (2016) (3)
Maintenance erlotinib (E) following first-line treatment with docetaxel, carboplatin and erlotinib in patients with ovarian carcinoma (2007) (3)
Homologous recombination (HR) deficiency, tumor BRCA1/2 mutations (tmBRCA) and association with response and outcome following platinum monotherapy in high grade serous ovarian cancer (HGSOC). (2015) (2)
A novel application of calcium electroporation to cutaneous manifestations of gynaecological cancer (2021) (2)
ZoptEC: Phase III study of zoptarelin doxorubicin (AEZS-108) in platinum-taxane pretreated endometrial cancer (Study AEZS-108-050). (2014) (2)
PISARRO: A EUTROC phase 1b study of APR-246 with carboplatin (C) and pegylated liposomal doxorubicin (PLD) in relapsed platinum-sensitive high grade serous ovarian cancer (HGSOC) (2016) (2)
Mutation and Protein Expression Biomarkers Correlate with Response to AKT Inhibition in a Phase I Trial of the Oral Pan AKT Inhibitor GSK2141795 (GSK795) in Patients (pts) with Platinum Resistant Ovarian Cancer (2011) (2)
A method for voltage measurements of cancerous vs non-cancerous omentum (2015) (2)
Molecular analysis of non-epithelial ovarian cancer by histologic subtype. (2014) (1)
A mathematical-descriptor of tumor-mesoscopic-structure from computed-tomography images annotates prognostic- and molecular-phenotypes of epithelial ovarian cancer (2019) (1)
A phase Ib study of NUC1031 and carboplatin for patients with recurrent ovarian cancer. (2016) (1)
Allele losses on chromosome 17 in ovarian tumours (1995) (1)
A randomized, double-blind, placebo-controlled, phase II study to assess the efficacy and safety of farletuzumab (MORAb-003) in combination with carboplatin plus either paclitaxel or pegylated liposomal doxorubicin (PLD) in subjects with low CA125 platinum-sensitive ovarian cancer. (2016) (1)
ProGem1: A phase I/II study of a first-in-class nucleotide, Acelarin, in patients with advanced solid tumors (2014) (1)
Impact of BRCA Mutation Status on Tumor Dissemination Pattern, Surgical Outcome and Patient Survival in Primary and Recurrent High-Grade Serous Ovarian Cancer: A Multicenter Retrospective Study by the Ovarian Cancer Therapy-Innovative Models Prolong Survival (OCTIPS) Consortium (2022) (1)
Characterising phenotypically relevant intratumoural heterogeneity in high grade serous ovarian cancer. (2015) (1)
Anti-tumour activity of a first-in-class agent NUC-1031 in patients with advanced cancer: results of a phase I study (2018) (1)
Surgical and Medical Management of Epithelial Ovarian Cancer (2018) (1)
602 AXL targeting with bemcentinb restores PD-1 blockade sensitivity of STK11/LKB1 mutant NSCLC through innate immune cell mediated expansion of TCF1+ CD8 T cells (2021) (1)
A statistical analysis of chromosome 11 and 17 loss of heterozygosity in epithelial ovarian cancer. (1996) (1)
5031 POSTER Combination chemotherapy with carboplatin and gemcitabine in patients in platinum-resistant ovarian cancer chemotherapy: a phase II study demonstrating inhibition of DNA cross-link repair by gemcitabine (2007) (1)
Correction: Safety and utility of image-guided research biopsies in relapsed high-grade serous ovarian carcinoma—experience of the BriTROC consortium (2019) (1)
Tilvestamab, a novel clinical stage humanized anti-AXL function blocking antibody (2020) (1)
OA01.07 A Phase II Study of the Oral Selective AXL Inhibitor Bemcentinib with Pembrolizumab in Patients with Advanced NSCLC (2021) (1)
Abstract CT204: Preliminary results from PiSARRO, a phase Ib/II study of APR-246, a mutant p53 reactivating small molecule, in combination with standard chemotherapy in platinum-sensitive ovarian cancer (2015) (1)
The Combination of AXL Inhibitor Bemcentinib and Low Dose Cytarabine Is Well Tolerated and Efficacious in Elderly Relapsed AML Patients: Update from the Ongoing BGBC003 Phase II Trial (NCT02488408) (2020) (1)
The genomic landscape of recurrent ovarian high grade serous carcinoma: the BriTROC-1 study (2022) (1)
[18F] Fluciclatide PET as a biomarker of clinical response to combination therapy of pazopanib and paclitaxel in patients with platinum-resistant or platinum-refractory advanced ovarian cancer: Results of a phase Ib study. (2019) (1)
Comprar Emerging Therapeutic Targets in Ovarian Cancer | Kaye, S. | 9781441972156 | Springer (2011) (1)
Clinical Cancer esearch cer Therapy : Clinical bition of Carboplatin-Induced DNA Interstrand Cross-link air by Gemcitabine in Patients Receiving these Drugs for R inum-Resistant Ovarian Cancer (2010) (1)
Ovarian cancer. (2003) (0)
Characterisation of tumour microvessel density during progression of high-grade serous ovarian cancer: clinico-pathological impact (an OCTIPS Consortium study). (2018) (0)
Abstract A47: DNA-PKcs is amplified in high-grade serous ovarian cancer (HGSC), correlates with poor outcome and drives resistance to platinum therapy via the AKT signaling pathway (2015) (0)
852P Exploring the correlation between AXL expression and gene expression molecular subtyping (GEMS) in high grade serous ovarian cancer (HGSOC) (2020) (0)
Molecular and cell genetic analysis of chromosome 11 in sporadic epithelial ovarian cancer (1997) (0)
Abstract LB-149: The OPCML tumor suppressor binds and negatively regulates the Axl receptor tyrosine kinase, sensitizing cells to foretinib in epithelial ovarian cancer (EOC) (2012) (0)
A new network for translational research in ovarian cancer. Interview by Helen Saul. (2010) (0)
OUTCOMES IN MUCINOUS OVARIAN CARCINOMAS: 10 YEARS OF EXPERIENCE IN A TERTIARY CENTRE (2013) (0)
Drug-Induced Exacerbation of Glomus Tumour Pain (2006) (0)
Immunological and gene therapy for ovarian cancer a technical overview. (2001) (0)
Targeting DNA damage response pathways to modulate pancreatic ductal adenocarcinoma sensitivity to DNA damaging agents (2016) (0)
Foreword (2014) (0)
Clinical value of bioelectrical properties of cancerous tissue in advanced epithelial ovarian cancer patients (2018) (0)
COPY-NUMBER SIGNATURES AND MUTATIONAL PROCESSES IN HIGH GRADE SEROUS OVARIAN CARCINOMA (2019) (0)
10th Biennial Helene Harris Memorial Trust meeting. (2006) (0)
Sustained Gas6/AXL signaling network in the mes subtype of ovarian cancer as a molecular subtype specific therapeutic target. (2016) (0)
Abstract POSTER-BIOL-1301: The receptor tyrosine kinase AXL modulates oncogenic signaling and epithelial mesenchymal transition in epithelial ovarian cancer (2015) (0)
OPCML, a systems regulator of receptor tyrosine kinases in ovarian and other cancers (2016) (0)
DESCRIBING INTRA-TUMOURAL HETEROGENEITY IN HIGH GRADE SEROUS OVARIAN CANCER (2017) (0)
Targeting genomic instability to identify molecular drivers of poor prognosis in cancer (2015) (0)
High complexity cytoreductive surgery for disseminated ovarian cancer in a UK setting: Challenges and possibilities (2016) (0)
Feasibility of Trials in Ovarian Cancer by Line of Therapy and Platinum Sensitivity (2013) (0)
0-39. Continuous 5-FU for locally advanced breast cancer - the Edinburgh Breast Unit experience (1997) (0)
Randomized phase II trial of farletuzumab plus chemotherapy versus placebo plus chemotherapy in low CA-125 platinum-sensitive ovarian cancer. (2023) (0)
Sustained platelet-sparing thromboprotective effect of weekly low dose paclitaxel allows effective, tolerable delivery of extended dose dense weekly carboplatin in platinum resistant/ refractory epithelial ovarian cancer (2011) (0)
316P Disruption of DNA double strand break repair by VCP inhibition in ovarian and pancreatic cancer (2016) (0)
The association between obesity and weight loss after bariatric surgery on the vaginal microbiota (2021) (0)
Abstract B51: Management of ascites via the alfa-pump closed system in platinum-resistant-ovarian-cancer (PROC): A model of sequential non-invasive tumor-cell sampling through the urinary bladder (2013) (0)
Scientific program (2002) (0)
A Phase Ib Open-Label, Dose-Escalation Study of NUC-1031 in Combination with Carboplatin for Recurrent Ovarian Cancer (2021) (0)
Survey of the management of borderline ovarian tumors in the United Kingdom (2012) (0)
75. Myeloablative therapy supported by peripheral blood stem cells (PBSC) in poor prognosis metastatic breast cancer — a phase 1/11 study (1995) (0)
Early stage mucinous ovarian carcinomas: 10 years of experience in a tertiary centre (2013) (0)
rOPCML-Fc as a potential tumor suppressive therapeutic agent for ovarian cancer (2022) (0)
Abstract NTOC-116: THE TUMOUR SUPPRESSOR PROTEIN OPCML ACTS AS A SENSITIZING AGENT IN ANTI–EGFR/HER2 THERAPY AND CISPLATIN TREATMENT IN OVARIAN CANCER (2017) (0)
MICROARRAY ANALYSIS OF OPCML TUMOUR SUPPRESSOR FUNCTION IN OVARIAN CANCER CELLS (2004) (0)
Yeast-2-Hybrid screen identifies Rab-interacting proteins as interacting prey targets for the OPCML tumour suppressor, highlighting a general theme of membrane trafficking (2008) (0)
Emerging roles for the GPI-anchored tumor suppressor OPCML in cancers (2020) (0)
WT1 as a target for immunotherapy inovarian cancer (2005) (0)
Ovarian cancer. (2002) (0)
Weeklydoxorubicin andcontinuous infusional 5-fluorouracil foradvanced breast cancer (2012) (0)
HMER_A_193996 47..67 (2019) (0)
Abstract 5107: Unravelling the complexity of individual cancer genomes (2012) (0)
P3 The expression of WWOX in pancreatic adenocarcinoma (2010) (0)
Fibronectin via Integrin and Decreases Attachment to In vivo Tumorigenicity Gene Expression Abolishes Ovarian Cancer (2009) (0)
Abstract 1616: The OPCML tumor suppressor negatively regulates a specific repertoire of 5 receptor tyrosine kinases via a novel proteasomal mechanism, and its recombinant derivative is a potent in-vivo anticancer protein therapy (2011) (0)
493PVCP/p97 inhibition is a therapeutic strategy to overcome drug resistance in ovarian and pancreatic cancers (2015) (0)
OBCAM, an IgLON cell adhesion molecule from 11q25, is frequently inactivated in sporadic epithelial ovarian cancer (2002) (0)
P-OGC39 The smell of oesophageal adenocarcinoma: opportunities for tests and treatments (2021) (0)
Identification of differentially expressed mRNAS associated with chromosome 11 transfer into the ovarian cancer cell line OVCAR3 (2002) (0)
290 Targeting AKT and DNA-PK as a therapeutic strategy in platinum resistant high-grade serous ovarian cancer (2020) (0)
Incidence and predictors of ovarian function recovery (OFR) in breast cancer (BC) patients with chemotherapy-induced amenorrhea (CIA) who switched from tamoxifen to exemestane (2013) (0)
Abstract IA15: Targeting acquired platinum resistance in ovarian cancer (2013) (0)
ASO Visual Abstract: Impact of BRCA Mutation Status on Tumor Dissemination Pattern, Surgical Outcome, and Patient Survival in Primary and Recurrent High-Grade Serous Ovarian Cancer (HGSOC). A Multicenter, Retrospective Study of the Ovarian Cancer Therapy—Innovative Models Prolong Survival (OCTIPS) C (2022) (0)
Edinburgh Research Explorer Carcinosarcoma of the ovary (2018) (0)
728: DNA-PKcs inhibition enhances response to DNA damaging agents and is associated with Rad51 downregulation (2014) (0)
EP964 Targeting AKT and DNA-PK as a therapeutic strategy in platinum resistant high-grade serous ovarian cancer (2019) (0)
Inactivating mutations and X-ray crystal structure of the tumor suppressor OPCML reveal cancer-associated functions (2019) (0)
Functional identification of RALDH2 dysregulation by cDNA representational difference analysis in chromosome 11 mediated growth suppression of ovarian cancer (2001) (0)
Abstract 2087: AXL inhibition enhances Type 1 interferon (IFN) response and potentiates chemo-immunotherapy (2022) (0)
Molecular physiology monitoring of ovarian cancer ex vivo. (2015) (0)
Abstract 4909: Adaptive oncology phase 1 study of first-in-class inhibitor of ataxia telangiectasia mutated protein kinase (ATM), in combination with olaparib (2018) (0)
421 The OPCML tumour suppressor functions as a repressor-adaptor, negatively regulating receptor tyrosine kinases in ovarian cancer (2010) (0)
gynecological cancer 663O IS ACTIVE IN WOMEN WITH ADVANCED EPITHELIAL OVARIAN, FALLOPIAN TUBE AND PERITONEAL CANCERS: RESULTS OF A PHASE II STUDY PLATINUM-SENSITIVE (2008) (0)
81 MNK 1 and 2 Inhibitors Are Active in Platinum-resistant Ovarian Cancer Cells (2012) (0)
Chemosensitisation of PDAC cell lines by the VCP inhibitor NMS-873 (2016) (0)
Patterns of relapse in patients treated with surgery followed by platinum based chemotherapy for advanced epithelial ovarian cancer (2008) (0)
Crystal structure of human Opioid Binding Protein/Cell Adhesion Molecule Like (OPCML) (2018) (0)
A randomized, double-blind, placebo-controlled, phase II study to assess the efficacy/safety of farletuzumab in combination with carboplatin plus paclitaxel or carboplatin plus pegylated liposomal doxorubicin (PLD) in women with low CA-125 platinum-sensitive ovarian cancer (2021) (0)
Best of ASCO® (2015) (0)
AUC 2 carboplatin in acquired platinum-resistant ovarian cancer with or without oral phenoxodiol , a sensitizer of platinum cytotoxicity : the phase III OVATUREmulticenter randomized study (2013) (0)
Abstract AP09: COPY-NUMBER SIGNATURES AND MUTATIONAL PROCESSES IN HIGH GRADE SEROUS OVARIAN CARCINOMA (2019) (0)
OPCML, a novel systems regulator of tyrosine kinase signaling in ovarian and other cancers (2012) (0)
Current clinical trials in ovarian cancer (2011) (0)
Effects of obesity and post-bariatric surgery weight loss on the vaginal microbiota (2021) (0)
Abstract PR04: DNA-PK inhibition resensitizes ovarian cancer cells to cisplatin in vivo and is associated with modulation of AKT pathway signaling (2013) (0)
PI3K/mTOR/MEK-targeted therapies in pancreatic and ovarian cancers (2016) (0)

This paper list is powered by the following services:

Other Resources About Hani Gabra

en.wikipedia.org

What Schools Are Affiliated With Hani Gabra?

Hani Gabra is affiliated with the following schools:

Hani Gabra's Academic­Influence.com Rankings

Why Is Hani Gabra Influential?

Hani Gabra's Published Works

Published Works

Other Resources About Hani Gabra

What Schools Are Affiliated With Hani Gabra?

Hani Gabra's AcademicInfluence.com Rankings